CRISHIGH SIGNALFINANCIAL10-K

CRIS underwent a dramatic financial restructuring with a massive 371% increase in outstanding shares (8.5M to 40M), severe cash depletion (-75%), and substantial liability reduction (-69%).

The quintupling of share count indicates massive dilution to existing shareholders, likely from distressed equity raises or debt conversions. The company's cash position collapsed from $20M to $5.1M while removing previous guidance about funding through Q4 2025, suggesting immediate liquidity concerns.

Comparing 2026-03-24 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

Despite revenue growing 305% to $9.9M and operating losses improving significantly (-$44.5M to -$5.7M), the financial picture reveals a company in distress. The 75% cash decline coupled with a 371% increase in shares outstanding indicates emergency capital raising through heavily dilutive measures. While total liabilities decreased 69% (possibly through debt-to-equity conversions), the dramatic share dilution and cash depletion signal severe financial stress that overshadows the operational improvements.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+305%
$2.4M→$9.9M

Strong top-line growth of 305% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
+191.1%
-$6.0M→$5.5M

Equity base grew 191.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Income
P&L
+87.2%
-$44.5M→-$5.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+82.5%
-$43.4M→-$7.6M

Net income grew 82.5% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
-74.7%
$20.0M→$5.1M

Cash declined 74.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-73.8%
$26.4M→$6.9M

Current assets declined 73.8% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-69.3%
$47.3M→$14.5M

Liabilities reduced 69.3% — deleveraging improves balance sheet strength and financial flexibility.

Total Assets
Balance Sheet
-51.6%
$41.3M→$20.0M

Total assets contracted 51.6% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
+31.8%
$13.7M→$18.0M

R&D investment increased 31.8% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
+31.2%
-$39.6M→-$27.2M

Operating cash flow surged 31.2% — exceptional cash generation, highest quality earnings signal.

LANGUAGE CHANGES
NEW — 2026-03-24
PRIOR — 2025-03-31
ADDED
As of March 20, 2026, there were 39,978,693 shares of the registrant s common stock outstanding.
3 Table o f Contents Other Information Unless otherwise indicated, or unless the context of the discussion requires otherwise, we use the terms we, us, our and similar references to refer to Curis, Inc.
4 Table o f Contents Risk Factor Summary Investment in our securities involves risk.
If we fail to maintain compliance with Nasdaq Capital Market s listing requirements, our common stock could be delisted from trading, which would decrease the liquidity of our common stock and our ability to raise additional capital.
BUSINESS Overview We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3.
+7 more — sign up free →
REMOVED
As of March 27, 2025, there were 8,487,818 shares of the registrant s common stock outstanding.
Other Information Unless otherwise indicated, or unless the context of the discussion requires otherwise, we use the terms we, us, our and similar references to refer to Curis, Inc.
The alleged events of default, or any future allegations of an event of default, under the Oberland Purchase Agreement could have a material adverse effect on our business, financial condition and stock price, including our ability to continue as a going concern.
As of December 31, 2024, we had $20.0 million in cash and cash equivalents.
In March 2025, we completed a registered direct offering and concurrent private placement for net proceeds of approximately $9.0 million.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →